Text Size

The Effect of Losartan Versus Amlodipine-based Therapy in Ischemic Stroke

This study has been completed.
Sponsor:
Information provided by:
Merck
ClinicalTrials.gov Identifier:
NCT00754429
First received: September 16, 2008
Last updated: July 29, 2009
Last verified: July 2009
History of Changes
  Purpose

To compare the effect of losartan vs amlodipine-based antihypertensive therapy on atherosclerotic inflammatory markers and cerebrovascular regulation in Ischemic stroke patients.


Condition Intervention Phase
Ischemic Stroke
 Drug: losartan
Drug: amlodipine
 Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: The Effect of Losartan Versus Amlodipine-based Antihypertensive Therapy on Atherosclerotic Inflammatory Markers and Cerebrovascular Regulation in Ischemic Stroke Patients

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Merck:

Primary Outcome Measures:
  • MCAFV and TCD for measuring cerebral autoregulatory indices at week 0, week 6, week 18 and week 30. [ Time Frame: At week 0, week 6, week 18 and week 30. ] [ Designated as safety issue: No ]

Enrollment: 40
Study Start Date: June 2004
Study Completion Date: July 2009
Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
Losartan 50mg qd for 30 weeks, if blood pressure > 140/90, or mean arterial Bp ≧ 15% of baseline, then add on diuretics.
 Drug: losartan
losartan 50mg qd for 30 weeks.
Other Names:
  • losartan potassium
  • COZAAR®
  • MK0954
Active Comparator: B
Amlodipine 5 mg q.d for 30 weeks, if blood pressure > 140/90, or mean arterial Bp ≧ 15% of baseline, then add on diuretics.
 Drug: amlodipine
amlodipine 5 mg q.d for 30 weeks.
Other Name: Norvasc

  Eligibility

Ages Eligible for Study:   20 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient With Tia Or Ischemic Stroke (Event Has Occurred More Thaan 4 Weeks But Less Than 24 Weeks, And Modified Rankin'S Scale, Mrs<=3) With Mild To Moderate Hypertension
  • Patient Has No Other Active Medical Problem, Which Might Of Itself Or By This Treatment Significantly Affect The Patient's Blood Pressure
  • The Blood Level Of Hscrp>0.2 Ng/Dl By Two Measurements Performed Respectively One-Week Apart

Exclusion Criteria:

  • Patients With Cardiac Arrhythmia
  • Diabetes Mellitus
  • Patient With Other Active Inflammatory Diseases Such As Rheumatoid Disease, Fever And Systemic Infection Which Will Confound The Level Of Serum CRP
  • Patients With Known Intolerance, Contraindication Or Hypersensitivity To Losartan, Amlodipine and Hydrochlorothiazide
  • Patient With Myocardial Infarction Within The Recent Three Months
  • Anatomy Abnormality Which Results In Poor Bilateral Temporal Acoustic Windows Which Prevent TCD Procedure
  • Patient Who Requires Continuous Medication With Alpha Blocking Agents
  • Concurrent Usage Of Acei
  • Poor Mental Function Or Any Other Reason To Expect Difficulty In Meeting The Requirements Of The Study
  • Concurrent Treatment With Other Lipid-Lowering Drug
  • Childbearing Potential Women Not Undergoing Adequate Contraceptive Control
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00754429

Sponsors and Collaborators
Merck
Investigators
Study Director: Medical Monitor Merck
  More Information

No publications provided

Responsible Party: Executive Vice President, Clinical and Quantitative Sciences, Merck & Co., Inc.
ClinicalTrials.gov Identifier: NCT00754429     History of Changes
Other Study ID Numbers: 2008_025, MK0954-338
Study First Received: September 16, 2008
Last Updated: July 29, 2009
Health Authority: Taiwan: National Bureau of Controlled Drugs

Additional relevant MeSH terms:
Ischemia
Stroke
Cerebral Infarction
Pathologic Processes
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Brain Infarction
Brain Ischemia
Antihypertensive Agents
 Amlodipine
Losartan
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Vasodilator Agents
Anti-Arrhythmia Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists

ClinicalTrials.gov processed this record on May 22, 2013